Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $8.2 million.

  • Pliant Therapeutics' Accumulated Expenses fell 1587.24% to $8.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 1587.24%. This contributed to the annual value of $12.4 million for FY2024, which is 2088.27% up from last year.
  • As of Q3 2025, Pliant Therapeutics' Accumulated Expenses stood at $8.2 million, which was down 1587.24% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Accumulated Expenses ranged from a high of $20.3 million in Q3 2022 and a low of $4.7 million during Q1 2023
  • Its 5-year average for Accumulated Expenses is $9.4 million, with a median of $8.2 million in 2024.
  • Per our database at Business Quant, Pliant Therapeutics' Accumulated Expenses surged by 11296.52% in 2022 and then crashed by 6112.68% in 2023.
  • Over the past 5 years, Pliant Therapeutics' Accumulated Expenses (Quarter) stood at $6.1 million in 2021, then soared by 41.4% to $8.7 million in 2022, then increased by 18.03% to $10.2 million in 2023, then rose by 20.88% to $12.4 million in 2024, then tumbled by 33.84% to $8.2 million in 2025.
  • Its Accumulated Expenses was $8.2 million in Q3 2025, compared to $7.2 million in Q2 2025 and $7.4 million in Q1 2025.